Provided by Tiger Trade Technology Pte. Ltd.

AKESO

95.350
-5.850-5.78%
Volume:21.57M
Turnover:2.04B
Market Cap:87.82B
PE:-66.40
High:97.950
Open:95.000
Low:91.900
Close:101.200
52wk High:159.800
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.60
T/O Rate:2.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.436
ROE:-13.59%
ROA:-4.57%
PB:8.88
PE(LYR):-66.40
PS:21.85

Loading ...

Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint

Reuters
·
Aug 28

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Dow Jones
·
Aug 28

Movement Alert|AKESO Falls 6.32% in Regular Trading, Profit-Taking After H1 Results Still Show Loss Despite 28% Revenue Growth

Market Focus
·
Aug 28

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live
·
Aug 28

Akeso Interim 2026 Results: Revenue Reaches RMB 1.81 Billion, Net Loss Narrows by 24.0%

Bulletin Express
·
Aug 27

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

Reuters
·
Aug 27

Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating

Deep News
·
Aug 27

Movement Alert|AKESO Rises 3.03% in Regular Trading, Ivonescimab Biliary Tract Cancer Phase 3 Meets Primary OS Endpoint Amid Interim Results Release

Market Focus
·
Aug 27

Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead

Stock News
·
Aug 26

China's Akeso Jumps on Progress of Immunotherapy Drug for Cancer Treatment

Reuters
·
Aug 26

AKESO Surges Over 9% in Session as Evonex Achieves Positive Phase III Results in Biliary Tract Cancer

Deep News
·
Aug 26

Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial

MT Newswires Live
·
Aug 26

Movement Alert|AKESO Rises 6.64% in Regular Trading, Phase III Trial for Ivonescimab in Biliary Tract Cancer Achieves Significant OS Benefit

Market Focus
·
Aug 26

Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint

Reuters
·
Aug 26

HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off

Stock News
·
Aug 26

AKESO's Novel Dual Antibody Achieves Positive Phase III Results in Biliary Tract Cancer, Marking First Solid Tumor Expansion Beyond Lung Cancer

Stock News
·
Aug 26

Akeso: Ivonescimab Plus Chemotherapy Delivers Statistically Significant OS Improvement in Phase III Biliary Tract Cancer Trial

Bulletin Express
·
Aug 26

Akeso - Ivonescimab Plus Chemo Meets Primary Endpoint with Significant Os Benefit in 1L BTC

THOMSON REUTERS
·
Aug 26

Akeso - Harmoni-Gi1 First Phase Iii Study to Show Significant Os Benefit Versus Global Standard in Biliary Tract Cancer

THOMSON REUTERS
·
Aug 26

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: Harmoni-Gi1 Meets Primary Endpoint

THOMSON REUTERS
·
Aug 26